Kura Oncology darlifarnib Phase 1a data
Analysis based on 6 articles · First reported Jun 03, 2026 · Last updated Jun 03, 2026
The positive preliminary Phase 1a data for darlifarnib from Kura Oncology, demonstrating high objective response rates in various cancers, is expected to positively impact Kura Oncology's stock price. This development could also attract further investment and collaboration opportunities within the biotechnology and pharmaceutical sectors, particularly for companies focused on cancer therapies.
Kura Oncology presented new clinical and translational data for darlifarnib at the 2026 American Society of Clinical Oncology Annual Meeting, positioning it as a potential foundational combination platform for KRAS-mutant cancers. Preliminary Phase 1a data from the FIT-001 study showed confirmed objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer patients when darlifarnib was combined with adagrasib. Clinical activity was observed in both KRAS inhibitor-naïve and pretreated patients, with tumor shrinkage in 77% of response-evaluable patients. Preclinical data also support darlifarnib's broad applicability across the evolving RAS inhibitor landscape. Kura Oncology plans to initiate a new platform study to accelerate the evaluation of darlifarnib across multiple targeted therapies and disease settings, with the first combination of darlifarnib plus daraxonrasib in KRAS-mutant pancreatic cancer expected to enter Phase 1a evaluation in early 2027. Troy E. Wilson and Mollie Leoni of Kura Oncology emphasized the drug's potential. The company also hosted a virtual investor event featuring David S. Hong to discuss these developments.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard